Comparative Pharmacology
Head-to-head clinical analysis: VASOSTRICT versus VASOXYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VASOSTRICT versus VASOXYL.
VASOSTRICT vs VASOXYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vasopressin is a synthetic analogue of the antidiuretic hormone (ADH) that acts on V1 receptors (vascular smooth muscle) to cause vasoconstriction, and on V2 receptors (renal collecting ducts) to increase water reabsorption. At high doses used in vasodilatory shock, it primarily increases systemic vascular resistance via V1 receptor activation.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction and increased blood pressure.
0.01-0.03 units/min IV continuous infusion, titrate to effect. Maximum 0.1 units/min.
Intravenous bolus: 0.1-0.2 mg per dose; intravenous infusion: 0.1-0.2 mg/min; intramuscular or subcutaneous: 0.5-1 mg per dose.
None Documented
None Documented
Terminal elimination half-life is approximately 10–20 minutes, with clinical effect terminated rapidly by enzymatic degradation (catechol-O-methyltransferase and monoamine oxidase) in the liver and other tissues.
Terminal elimination half-life is 2.5-3.0 hours; clinically relevant for dosing intervals in hypotension management.
Primarily renal (90–95% as inactive metabolites); minor biliary/fecal excretion (<5%).
Primarily renal excretion as unchanged drug and metabolites (phenylephrine is deaminated by MAO). Approximately 80-85% excreted in urine within 24 hours; negligible biliary/fecal elimination.
Category C
Category C
Vasopressor
Vasopressor